Factors associated with healthcare utilization costs for statin therapy - A pilot study in Hong Kong

International Journal of Clinical Pharmacology and Therapeutics

Volumn 44, Issue 10, 2006, Pages 484-488

  Cheng, C W R ^a   Chan, J C N ^a   Tomlinson, B ^a   Woo, K S ^a   You, Joyce H S ^a  

^a Prince of Wales Hospital   (Hong Kong)

Author keywords

Chinese patients; Cost analysis; Statin

Indexed keywords

ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; SIMVASTATIN;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL FEATURE; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY RISK; COST EFFECTIVENESS ANALYSIS; DEMOGRAPHY; DIABETES MELLITUS; DIAGNOSTIC KIT; DRUG COST; EFFECT SIZE; FEMALE; GENDER BIAS; HEALTH CARE COST; HEALTH CARE ORGANIZATION; HEALTH CARE UTILIZATION; HIGH RISK PATIENT; HONG KONG; HUMAN; HYPERLIPIDEMIA; ISCHEMIC HEART DISEASE; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MONITOR; MONOTHERAPY; OBSERVATIONAL STUDY; PATIENT COMPLIANCE; PILOT STUDY; PREDICTION; RISK ASSESSMENT; RISK FACTOR; SOCIOECONOMICS; STATISTICAL SIGNIFICANCE;

EID: 33749603950     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP44484     Document Type: Article

References (22)

1. Black D, Davidson M, Koren M, Bakker-Arkema R, Tresh P, McLain R et al. Cost effectiveness of treatment to National Cholesterol Education Panel (NCEP) targets with HMG-CoA reductase inhibitors. Pharmacoeconomics. 1997; 12: 278-285.
2. Cramer JA, Mattson RH, Prevey ML, Scheyer RD, Ouellette VL. How often is medication taken as prescribed? A novel assessment technique. JAMA. 1989; 261: 3273-3277.
3. Downs JR, Clearfield M, Weis S et al. for the AFCAPS/TexCAPS Research Group. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/ TexCAPS. JAMA. 1998; 279. 1615-1622.
4. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 2001; 285: 2486-2497.
5. Franco O, Peeters A, Looman CWN, Bonneux L. Cost effectiveness of statins in coronary heart disease. J Epidemiol Community Health. 2005; 59: 927-933.
6. Ganz DA, Kuntz KM, Jacobson GA, Avorn J. Cost-effectiveness of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor therapy in older patients with myocardial infarction. Ann Intern Med. 2000; 132: 780-787.
7. Government of Hong Kong, SAR, China. Website: http://www.info.gov.hk/dh/ diseases/index.htm. Accessed November 3, 2003.
8. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high risk individuals: a randomized placebo-controlled trial. Lancet. 2002; 360: 7-22.
9. Heerey AM, Barry M, Effect of non-adherence to statins on associated cost effectiveness. Value in Health. 2002; 5:176.
10. Hong Kong Government Logistics Department. Website: http://www.info.gov.hk. Accessed August 2004.
11. Huse DM, Russell MW, Miller JD, Kraemer DF, D'Agostino RB, Ellison RC et al. Cost-effectiveness of statins. Am J Cardiol. 1998; 82: 1357-1363.
12. Johannesson M, Jonsson B, Kjekshus J, Olsson AG, Pedersen TR, Wedel H. Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. Scandinavian Simvastatin Survival Study Group. N Engl J Med. 1997; 336: 332-336.
13. Koren MJ, Smith DG, Hunninghake DB, Davidson MH, McKenney JM, Weiss SR, Black DM. The cost of reaching National Cholesterol Education Program (NCEP) goals in hypercholesterolaemic patients. A comparison of atorvastatin, simvastatin, lovastatin and fluvastatin. Pharmacoeconomics. 1998; 14: 59-70.
14. Oster G, Borok GM, Menzin J, Heyse JF, Epstein RS, Quinn V et al. Cholesterol-reduction intervention study (CRIS): a randomized trial to assess effectiveness and costs in clinical practice. Arch Intern Med. 1996; 156: 731-739.
15. Peterson AM, McGhan WF. Pharmacoeconomic impact of non-compliance with statins. Pharmacoeconomics. 2005; 23: 13-25.
16. Pignone M, Earnshaw S, Tice JA, Pletcher MJ. Aspirin, statins, or both drugs for the primary prevention of coronary heart disease events in men: A cost-utility analysis. Ann Intern Med. 2006; 144: 326-336.
17. Prosser LA, Stinnett AA, Goldman PA, Williams LW, Hunink MGM, Goldman L et al. Cost-effectiveness of cholesterol-lowering therapies according to selected patient characteristics. Ann Intern Med. 2000; 132: 769-779.
18. Sacks FM, Pfeffer MA, Moye LA et al. for the Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patientts with average cholesterol levels. N Engl J Med. 1996; 335: 1001-1009.
19. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994; 344: 1383-1389.
20. Shepherd J, Cobbe SM, Ford I et al. for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease in men with hypercholesterolemia. N Engl J Med. 1995; 333: 1301-1307.
21. The Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998; 339: 1349-1357.
22. Zunker RJ, Carlson DL. Economics of using pharmacists as advisers to physicians in risk-sharing contracts. Am J Health Syst Pharm. 2000; 57: 753-755.